Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Das Thema chronische Unterbauch- und Viszeralschmerzen wird im Live-Webinar am 7. Mai von 17.30 bis 19 Uhr aus internistischer, gynäkologischer und psychologisch-neurowissenschaftlicher Perspektive beleuchtet. Besprochen werden krankheitsbedingte Ursachen, Mechanismen der kognitiven Schmerzmodulation sowie mögliche Therapieoptionen. Die Fortbildung ist mit 2 CME-Punkten zertifiziert. Melden Sie sich jetzt an!
Erweiterte Suche
Anmelden
nach oben
Tumor Biology
Erschienen in: Tumor Biology 5/2014

01.05.2014 | Review

Low circulating adiponectin levels in women with polycystic ovary syndrome: an updated meta-analysis

verfasst von: Shan Li, Xiamei Huang, Huizhi Zhong, Qiliu Peng, Siyuan Chen, Yantong Xie, Xue Qin, Aiping Qin

Erschienen in: Tumor Biology | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

Adiponectin, as an important adipocytokine, plays a pivotal role in the regulation of insulin sensitivity and metabolism. It has been reported that circulating adiponectin levels were decreased in women with polycystic ovary syndrome (PCOS). However, the results remained inconsistent. In order to derive a more precise estimation of this relationship, a large meta-analysis was performed in this study. A comprehensive systematic electronic search was conducted in electronic databases PubMed, EMBASE, and Web of Science up to November 30, 2013. Pooled weighted mean differences (WMDs) with 95 % confidence intervals (CIs) were calculated to estimate the strength of the association. A meta-analysis technique was used to study 38 trials involving 1,944 PCOS women and 1,654 healthy controls. Overall pooled adiponectin levels in women with PCOS were significantly reduced compared with healthy controls (WMD −2.67, 95 % CI −3.22 to −2.13; P = 0.000), yet with significant heterogeneity across studies (I2 = 95.9 %, P = 0.000). In subgroup analysis by HOMA-IR ratio and total testosterone ratio, inconsistent results were presented. No single study was found to affect the overall results by sensitivity testing. Meta-regression suggested that BMI might contribute little to the heterogeneity between including studies. Cumulative meta-analysis demonstrated the reliability and stability of the meta-analysis results. No evidence of publication bias was observed. Our meta-analysis suggested that circulating adiponectin levels in women with PCOS were significantly lower than those in healthy controls, which indicated that circulating adiponectin might play a role in the development of PCOS.
Literatur
1.
Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis, and diagnosis. Nat Rev Endocrinol. 2011;7:219–31.CrossRefPubMed
2.
Carmina E, Azziz R. Diagnosis, phenotype, and prevalence of polycystic ovary syndrome. Fertil Steril. 2006;86 Suppl 1:S7–8.CrossRefPubMed
3.
Chang WY, Knochenhauer ES, Bartolucci AA, Azziz R. Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups. Fertil Steril. 2005;83:1717–23.CrossRefPubMed
4.
Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012;33:981–1030.CrossRefPubMedPubMedCentral
5.
Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes, and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010;16:347–63.CrossRefPubMed
6.
Diamanti-Kandarakis E, Papavassiliou AG, Kandarakis SA, Chrousos GP. Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol Metab. 2007;18:280–5.CrossRefPubMed
7.
Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91:48–53.CrossRefPubMed
8.
Toulis KA, Goulis DG, Mintziori G, Kintiraki E, Eukarpidis E, Mouratoglou SA, et al. Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome. Hum Reprod Update. 2011;17:741–60.CrossRefPubMed
9.
Gulcelik NE, Aral Y, Serter R, Demir Y, Culha C. Adiponectin is an independent determinant of insulin resistance in women with polycystic ovary syndrome. Gynecol Endocrinol. 2006;22:511–5.CrossRefPubMed
10.
Gulcelik NE, Aral Y, Serter R, Koc G. Association of hypoadiponectinemia with metabolic syndrome in patients with polycystic ovary syndrome. J Natl Med Assoc. 2008;100:64–8.CrossRefPubMed
11.
O’Connor A, Phelan N, Tun TK, Boran G, Gibney J, Roche HM. High-molecular-weight adiponectin is selectively reduced in women with polycystic ovary syndrome independent of body mass index and severity of insulin resistance. J Clin Endocrinol Metab. 2010;95:1378–85.CrossRefPubMed
12.
Sharifi F, Hajihosseini R, Mazloomi S, Amirmogaddami H, Nazem H. Decreased adiponectin levels in polycystic ovary syndrome, independent of body mass index. Metab Syndr Relat Disord. 2010;8:47–52.CrossRefPubMed
13.
Tao T, Wickham 3rd EP, Fan W, Yang J, Liu W. Distribution of adiponectin multimeric forms in Chinese women with polycystic ovary syndrome and their relation to insulin resistance. Eur J Endocrinol. 2010;163:399–406.CrossRefPubMedPubMedCentral
14.
Bohler Jr H, Mokshagundam S, Winters SJ. Adipose tissue and reproduction in women. Fertil Steril. 2010;94:795–825.CrossRefPubMed
15.
Michalakis KG, Segars JH. The role of adiponectin in reproduction: from polycystic ovary syndrome to assisted reproduction. Fertil Steril. 2010;94:1949–57.CrossRefPubMedPubMedCentral
16.
Lagaly DV, Aad PY, Grado-Ahuir JA, Hulsey LB, Spicer LJ. Role of adiponectin in regulating ovarian theca and granulosa cell function. Mol Cell Endocrinol. 2008;284:38–45.CrossRefPubMed
17.
Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2009;302:179–88.CrossRefPubMed
18.
Zhang BC, Liu WJ, Che WL, Xu YW. Serum total adiponectin level and risk of cardiovascular disease in Han Chinese populations: a meta-analysis of 17 case–control studies. Clin Endocrinol (Oxf). 2012;77:370–8.CrossRef
19.
Kim DH, Kim C, Ding EL, Townsend MK, Lipsitz LA. Adiponectin levels and the risk of hypertension: a systematic review and meta-analysis. Hypertension. 2013;62:27–32.CrossRefPubMedPubMedCentral
20.
Escobar-Morreale HF, Villuendas G, Botella-Carretero JI, Alvarez-Blasco F, Sanchon R, Luque-Ramirez M, et al. Adiponectin and resistin in PCOS: a clinical, biochemical, and molecular genetic study. Hum Reprod. 2006;21:2257–65.CrossRefPubMed
21.
Orio Jr F, Palomba S, Cascella T, Milan G, Mioni R, Pagano C, et al. Adiponectin levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:2619–23.CrossRefPubMed
22.
Panidis D, Kourtis A, Farmakiotis D, Mouslech T, Rousso D, Koliakos G. Serum adiponectin levels in women with polycystic ovary syndrome. Hum Reprod. 2003;18:1790–6.CrossRefPubMed
23.
Carmina E, Orio F, Palomba S, Cascella T, Longo RA, Colao AM, et al. Evidence for altered adipocyte function in polycystic ovary syndrome. Eur J Endocrinol. 2005;152:389–94.CrossRefPubMed
24.
Toulis KA, Goulis DG, Farmakiotis D, Georgopoulos NA, Katsikis I, Tarlatzis BC, et al. Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis. Hum Reprod Update. 2009;15:297–307.CrossRefPubMed
25.
Li X, Huang HY, Ma D, Zhu MW. Lin JF: [correlations between adipocytokines and insulin resistance in women with polycystic ovary syndrome]. Zhonghua Yi Xue Za Zhi. 2009;89:2607–10.PubMed
26.
Pinhas-Hamiel O, Singer S, Pilpel N, Koren I, Boyko V, Hemi R, et al. Adiponectin levels in adolescent girls with polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf). 2009;71:823–7.CrossRef
27.
Wang Y. Yu P: [clinical significance and changes of serum visfatin, adiponectin, and leptin levels in patients with polycystic ovarian syndrome]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2009;34:72–5.PubMed
28.
Yilmaz M, Bukan N, Demirci H, Ozturk C, Kan E, Ayvaz G, et al. Serum resistin and adiponectin levels in women with polycystic ovary syndrome. Gynecol Endocrinol. 2009;25:246–52.CrossRefPubMed
29.
Arikan S, Bahceci M, Tuzcu A, Kale E, Gokalp D. Serum resistin and adiponectin levels in young non-obese women with polycystic ovary syndrome. Gynecol Endocrinol. 2010;26:161–6.CrossRefPubMed
30.
Demirci H, Yilmaz M, Ergun MA, Yurtcu E, Bukan N, Ayvaz G. Frequency of adiponectin gene polymorphisms in polycystic ovary syndrome and the association with serum adiponectin, androgen levels, insulin resistance, and clinical parameters. Gynecol Endocrinol. 2010;26:348–55.CrossRefPubMed
31.
Tarkun I, Dikmen E, Cetinarslan B, Canturk Z. Impact of treatment with metformin on adipokines in patients with polycystic ovary syndrome. Eur Cytokine Netw. 2010;21:272–7.PubMed
32.
Cekmez F, Cekmez Y, Pirgon O, Canpolat FE, Aydinoz S, Metin Ipcioglu O, et al. Evaluation of new adipocytokines and insulin resistance in adolescents with polycystic ovary syndrome. Eur Cytokine Netw. 2011;22:32–7.PubMed
33.
Choi JH, Rhee EJ, Kim KH, Woo HY, Lee WY, Sung KC. Plasma omentin-1 levels are reduced in non-obese women with normal glucose tolerance and polycystic ovary syndrome. Eur J Endocrinol. 2011;165:789–96.CrossRefPubMed
34.
Olszanecka-Glinianowicz M, Kuglin D, Dabkowska-Huc A, Skalba P. Serum adiponectin and resistin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2011;154:51–6.CrossRefPubMed
35.
Pangaribuan B, Yusuf I, Mansyur M, Wijaya A. Serum adiponectin and resistin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Ther Adv Endocrinol Metab. 2011;2:235–45.CrossRefPubMedPubMedCentral
36.
Savastano S, Valentino R, Di Somma C, Orio F, Pivonello C, Passaretti F, et al. Serum 25-hydroxyvitamin D levels, phosphoprotein enriched in diabetes gene product (ped/pea-15), and leptin-to-adiponectin ratio in women with PCOS. Nutr Metab (Lond). 2011;8:84.CrossRef
37.
38.
Wickham 3rd EP, Cheang KI, Clore JN, Baillargeon JP, Nestler JE. Total and high-molecular weight adiponectin in women with the polycystic ovary syndrome. Metabolism. 2011;60:366–72.CrossRefPubMed
39.
Yasar L, Ekin M, Gedikbasi A, Erturk AD, Savan K, Ozdemir A, et al. Serum adiponectin levels in high school girls with polycystic ovary syndrome and hyperandrogenism. J Pediatr Adolesc Gynecol. 2011;24:90–3.CrossRefPubMed
40.
Aydogdu A, Uckaya G, Tasci I, Baysan O, Tapan S, Bugan B, et al. The relationship of epicardial adipose tissue thickness to clinical and biochemical features in women with polycystic ovary syndrome. Endocr J. 2012;59:509–16.CrossRefPubMed
41.
Golbahar J, Das NM, Al-Ayadhi MA, Gumaa K. Leptin-to-adiponectin, adiponectin-to-leptin ratios, and insulin are specific and sensitive markers associated with polycystic ovary syndrome: a case–control study from Bahrain. Metab Syndr Relat Disord. 2012;10:98–102.CrossRefPubMed
42.
Mazloomi S, Sharifi F, Hajihosseini R, Kalantari S, Mazloomzadeh S. Association between hypoadiponectinemia and low serum concentrations of calcium and vitamin d in women with polycystic ovary syndrome. ISRN Endocrinol. 2012;2012:949427.CrossRefPubMedPubMedCentral
43.
Spanos N, Tziomalos K, Macut D, Koiou E, Kandaraki EA, Delkos D, et al. Adipokines, insulin resistance and hyperandrogenemia in obese patients with polycystic ovary syndrome: cross-sectional correlations and the effects of weight loss. Obes Facts. 2012;5:495–504.CrossRefPubMed
44.
Woo HY, Kim KH, Rhee EJ, Park H, Lee MK. Differences of the association of anti-mullerian hormone with clinical or biochemical characteristics between women with and without polycystic ovary syndrome. Endocr J. 2012;59:781–90.CrossRefPubMed
45.
Kale-Gurbuz T, Akhan SE, Bastu E, Telci A, Iyibozkurt AC, Topuz S. Adiponectin, leptin and ghrelin levels in obese adolescent girls with polycystic ovary syndrome. J Pediatr Adolesc Gynecol. 2013;26:27–30.CrossRefPubMed
46.
Lee H, Oh JY, Sung YA. Adipokines, insulin-like growth factor binding protein-3 levels, and insulin sensitivity in women with polycystic ovary syndrome. Korean J Intern Med. 2013;28:456–63.CrossRefPubMedPubMedCentral
47.
Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (moose) group. JAMA. 2000;283:2008–12.CrossRefPubMed
48.
49.
Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13.CrossRefPubMedPubMedCentral
50.
51.
Li S, Liu Y, Peng Q, Xie L, Wang J, Qin X. Chewing gum reduces postoperative ileus following abdominal surgery: a meta-analysis of 17 randomized controlled trials. J Gastroenterol Hepatol. 2013;28:1122–32.CrossRefPubMed
52.
Shen W, Li T, Hu Y, Liu H, Song M. Calpain-10 genetic polymorphisms and polycystic ovary syndrome risk: a meta-analysis and meta-regression. Gene. 2013;531:426–34.CrossRefPubMed
53.
54.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.CrossRefPubMed
55.
Song F, Khan KS, Dinnes J, Sutton AJ. Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy. Int J Epidemiol. 2002;31:88–95.CrossRefPubMed
56.
Panidis D, Farmakiotis D, Rousso D, Koliakos G, Kaltsas T, Krassas G. Decrease in adiponectin levels in women with polycystic ovary syndrome after an oral glucose tolerance test. Fertil Steril. 2005;83:232–4.CrossRefPubMed
57.
Lecke SB, Mattei F, Morsch DM, Spritzer PM. Abdominal subcutaneous fat gene expression and circulating levels of leptin and adiponectin in polycystic ovary syndrome. Fertil Steril. 2011;95:2044–9.CrossRefPubMed
58.
Safar FH, Mojiminiyi OA, Al-Rumaih HM, Diejomaoh MF. Computational methods are significant determinants of the associations and definitions of insulin resistance using the homeostasis model assessment in women of reproductive age. Clin Chem. 2011;57:279–85.CrossRefPubMed
59.
Pepene CE. Evidence for visfatin as an independent predictor of endothelial dysfunction in polycystic ovary syndrome. Clin Endocrinol (Oxf). 2012;76:119–25.CrossRef
60.
Singh S, Akhtar N, Ahmad J. Plasma adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a case–control study. Diabetes Metab Syndr. 2012;6:207–11.CrossRefPubMed
61.
Lecke SB, Morsch DM, Spritzer PM: association between adipose tissue expression and serum levels of leptin and adiponectin in women with polycystic ovary syndrome. Genet Mol Res 2013; 12.
62.
Lecke SB, Morsch DM, Spritzer PM. Association between adipose tissue expression and serum levels of leptin and adiponectin in women with polycystic ovary syndrome. Genet Mol Res. 2013;12:4292–6.CrossRefPubMed
63.
Jensterle M, Weber M, Pfeifer M, Prezelj J, Pfutzner A, Janez A. Assessment of insulin resistance in young women with polycystic ovary syndrome. Int J Gynaecol Obstet. 2008;102:137–40.CrossRefPubMed
64.
Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93:2670–8.CrossRefPubMed
65.
Majuri A, Santaniemi M, Rautio K, Kunnari A, Vartiainen J, Ruokonen A, et al. Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study. Eur J Endocrinol. 2007;156:263–9.CrossRefPubMed
66.
Lewandowski KC, Szosland K, O’Callaghan C, Tan BK, Randeva HS, Lewinski A. Adiponectin and resistin serum levels in women with polycystic ovary syndrome during oral glucose tolerance test: a significant reciprocal correlation between adiponectin and resistin independent of insulin resistance indices. Mol Genet Metab. 2005;85:61–9.CrossRefPubMed
67.
Aigner E, Bachofner N, Klein K, De Geyter C, Hohla F, Patsch W, et al. Retinol-binding protein 4 in polycystic ovary syndrome–association with steroid hormones and response to pioglitazone treatment. J Clin Endocrinol Metab. 2009;94:1229–35.CrossRefPubMed
68.
Chang CY, Chen MJ, Yang WS, Yeh CY, Ho HN, Chen SU, et al. Hypoadiponectinemia: a useful marker of dyslipidemia in women with polycystic ovary syndrome. Taiwan J Obstet Gynecol. 2012;51:583–90.CrossRefPubMed
69.
Tao T, Xu B, Liu W. Ovarian HMW adiponectin is associated with folliculogenesis in women with polycystic ovary syndrome. Reprod Biol Endocrinol. 2013;11:99.CrossRefPubMedPubMedCentral
70.
Panidis D, Kourtis A, Kukuvitis A, Farmakiotis D, Xita N, Georgiou I, et al. Association of the t45g polymorphism in exon 2 of the adiponectin gene with polycystic ovary syndrome: role of delta4-androstenedione. Hum Reprod. 2004;19:1728–33.CrossRefPubMed
71.
Haap M, Machicao F, Stefan N, Thamer C, Tschritter O, Schnuck F, et al. Genetic determinants of insulin action in polycystic ovary syndrome. Exp Clin Endocrinol Diabetes. 2005;113:275–81.CrossRefPubMed
72.
Zhang N, Shi YH, Hao CF, Gu HF, Li Y, Zhao YR, et al. Association of +45g15g(t/g) and +276(g/t) polymorphisms in the adipoq gene with polycystic ovary syndrome among Han Chinese women. Eur J Endocrinol. 2008;158:255–60.CrossRefPubMed
73.
Lauria PB, Del Puerto HL, Reis AM, Candido AL, Reis FM, Tao T, et al. Low plasma atrial natriuretic peptide: a new piece in the puzzle of polycystic ovary syndrome ovarian HMW adiponectin is associated with folliculogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2013;98:4882–9.CrossRefPubMed
74.
Glintborg D, Frystyk J, Hojlund K, Andersen KK, Henriksen JE, Hermann AP, et al. Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo-controlled study in polycystic ovary syndrome. Clin Endocrinol (Oxf). 2008;68:165–74.
75.
Barber TM, Hazell M, Christodoulides C, Golding SJ, Alvey C, Burling K, et al. Serum levels of retinol-binding protein 4 and adiponectin in women with polycystic ovary syndrome: associations with visceral fat but no evidence for fat mass-independent effects on pathogenesis in this condition. J Clin Endocrinol Metab. 2008;93:2859–65.CrossRefPubMed
76.
Glintborg D, Andersen M, Hagen C, Frystyk J, Hulstrom V, Flyvbjerg A, et al. Evaluation of metabolic risk markers in polycystic ovary syndrome (PCOS). Adiponectin, ghrelin, leptin, and body composition in hirsute PCOS patients and controls. Eur J Endocrinol. 2006;155:337–45.CrossRefPubMed
77.
Ducluzeau PH, Cousin P, Malvoisin E, Bornet H, Vidal H, Laville M, et al. Glucose-to-insulin ratio rather than sex hormone-binding globulin and adiponectin levels is the best predictor of insulin resistance in nonobese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:3626–31.CrossRefPubMed
78.
Tan BK, Chen J, Digby JE, Keay SD, Kennedy CR, Randeva HS. Upregulation of adiponectin receptor 1 and 2 MRNA and protein in adipose tissue and adipocytes in insulin-resistant women with polycystic ovary syndrome. Diabetologia. 2006;49:2723–8.CrossRefPubMed
79.
Aydogdu A, Tasci I, Tapan S, Sonmez A, Aydogan U, Akbulut H, et al. Women with polycystic ovary syndrome have increased plasma chitotriosidase activity: a pathophysiological link between inflammation and impaired insulin sensitivity? Exp Clin Endocrinol Diabetes. 2012;120:261–5.CrossRefPubMed
80.
Orio Jr F, Palomba S, Cascella T, Di Biase S, Labella D, Russo T, et al. Lack of an association between peroxisome proliferator-activated receptor-gamma gene pro12ala polymorphism and adiponectin levels in the polycystic ovary syndrome. J Clin Endocrinol Metab. 2004;89:5110–5.CrossRefPubMed
81.
Beckman JA, Goldfine AB, Dunaif A, Gerhard-Herman M, Creager MA. Endothelial function varies according to insulin resistance disease type. Diabetes Care. 2007;30:1226–32.CrossRefPubMed
82.
Moran LJ, Noakes M, Clifton PM, Wittert GA, Belobrajdic DP, Norman RJ. C-reactive protein before and after weight loss in overweight women with and without polycystic ovary syndrome. J Clin Endocrinol Metab. 2007;92:2944–51.CrossRefPubMed
83.
Shroff R, Kerchner A, Maifeld M, Van Beek EJ, Jagasia D, Dokras A. Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis. J Clin Endocrinol Metab. 2007;92:4609–14.CrossRefPubMed
84.
Aroda V, Ciaraldi TP, Chang SA, Dahan MH, Chang RJ, Henry RR. Circulating and cellular adiponectin in polycystic ovary syndrome: relationship to glucose tolerance and insulin action. Fertil Steril. 2008;89:1200–8.CrossRefPubMed
85.
Thomann R, Rossinelli N, Keller U, Tirri BF, De Geyter C, Ruiz J, et al. Differences in low-grade chronic inflammation and insulin resistance in women with previous gestational diabetes mellitus and women with polycystic ovary syndrome. Gynecol Endocrinol. 2008;24:199–206.CrossRefPubMed
86.
Aroda VR, Ciaraldi TP, Burke P, Mudaliar S, Clopton P, Phillips S, et al. Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial. J Clin Endocrinol Metab. 2009;94:469–76.CrossRefPubMed
87.
Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–63.CrossRefPubMed
88.
Brassard M, AinMelk Y, Baillargeon JP. Basic infertility including polycystic ovary syndrome. Med Clin North Am. 2008;92:1163–92. xi.CrossRefPubMed
89.
Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Weyer C, Lindsay RS, et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes. 2002;51:1884–8.CrossRefPubMed
90.
Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7:941–6.CrossRefPubMed
91.
Pajvani UB, Scherer PE. Adiponectin: systemic contributor to insulin sensitivity. Curr Diab Rep. 2003;3:207–13.CrossRefPubMed
Metadaten
Titel
Low circulating adiponectin levels in women with polycystic ovary syndrome: an updated meta-analysis
verfasst von
Shan Li
Xiamei Huang
Huizhi Zhong
Qiliu Peng
Siyuan Chen
Yantong Xie
Xue Qin
Aiping Qin
Publikationsdatum
01.05.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 5/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1595-0

Weitere Artikel der Ausgabe 5/2014

Tumor Biology 5/2014 Zur Ausgabe

Research Article

Risk of severe diarrhea with dual anti-HER2 therapies: a meta-analysis

Research Article

Identification of sequence polymorphisms in the mitochondrial displacement loop as risk factors for sporadic and familial breast cancer

Research Article

ChIP-seq predicted estrogen receptor biding sites in human breast cancer cell line MCF7

Research Article

The mannose-sensitive hemagglutination pilus strain of Pseudomonas aeruginosa shift peritoneal milky spot macrophages towards an M1 phenotype to dampen peritoneal dissemination

Research Article

Astrocyte elevated gene-1 (AEG-1) shRNA sensitizes Huaier polysaccharide (HP)-induced anti-metastatic potency via inactivating downstream P13K/Akt pathway as well as augmenting cell-mediated immune response

Editorial

Letter regarding Wen X.Y. et al. entitled “Matrix metalloproteinase 2 expression and survival of patients with osteosarcoma: a meta-analysis”

Neu im Fachgebiet Onkologie

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise